GlassScriptPhysician profile
Donald J Brooks
NPI 1801865175
$3,715.73
in general payments reported to CMS, 2019-2025
48 companies · $570 in 2025
The $570 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $305 · 2021: $61.07 · 2022: $433 · 2023: $468 · 2024: $963 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.49 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $410.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $297.51 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $280.69 | 2020-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $277.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $267.96 | 2019-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $241.05 | 2022-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $206.42 | 2019-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $206.41 | 2019-2025 | |
| Celgene Corporation | $170.88 | 2023-2024 | Reblozyl |
| Gilead Sciences, INC. | $104.72 | 2019-2024 | Trodelvy |
| Emd Serono, INC. | $93.75 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $76.53 | 2022-2025 | Monoferric |
| Sumitomo Pharma America, INC. | $73.76 | 2024 | Orgovyx |
| Genentech USA, INC. | $71.55 | 2019-2024 | Phesgo, Perjeta |
| Glaxosmithkline, LLC. | $64.42 | 2024-2025 | Jemperli, Zejula, Blenrep |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.